Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3–5
Autor: | Marcelo Mazza do Nascimento, Bengt Lindholm, Miguel C. Riella, Anna Bjällmark, Gustavo Lenci Marques, Marcia Olandoski, Matilda Larsson, Shirley Yumi Hayashi |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Male
musculoskeletal diseases medicine.medical_specialty Science 030232 urology & nephrology Disease 030204 cardiovascular system & hematology Gastroenterology Article Calcification 03 medical and health sciences 0302 clinical medicine Osteoprotegerin Diabetes mellitus Internal medicine Chronic kidney disease medicine Humans Cumulative incidence Prospective Studies Renal Insufficiency Chronic Cause of death Aged Multidisciplinary Receiver operating characteristic business.industry Mortality rate Middle Aged medicine.disease Cardiovascular diseases Medicine Female business Biomarkers Kidney disease Follow-Up Studies |
Zdroj: | Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021) Scientific Reports |
ISSN: | 2045-2322 |
Popis: | Cardiovascular disease (CVD) is the leading cause of death in patients with chronic kidney disease (CKD). Osteoprotegerin (OPG), known to regulate bone mass by inhibiting osteoclast differentiation and activation, might also play a role in vascular calcification. Increased circulating OPG levels in patients with CKD are associated with aortic calcification and increased mortality. We assessed the predictive role of OPG for all-cause and cardiovascular mortality in patients with CKD stages 3–5 over a 5-year follow-up period. We evaluated the relationship between OPG and all-cause and cardiovascular mortality in 145 CKD patients (stages 3–5) in a prospective observational follow-up study. Inflammation markers, including high-sensitivity C-reactive protein, standard echocardiography, and estimation of intima-media thickness in the common carotid artery, were assessed at baseline, and correlations with OPG levels were determined. The cutoff values for OPG were defined using ROC curves for cardiovascular mortality. Survival was assessed during follow up lasting for up to 5.5 years using Fine and Gray model. A total of 145 (89 men; age 58.9 ± 15.0 years) were followed up. The cutoff value for OPG determined using ROC was 10 pmol/L for general causes mortality and 10.08 pmol/L for CV causes mortality. Patients with higher serum OPG levels presented with higher mortality rates compared to patients with lower levels. Aalen–Johansen cumulative incidence curve analysis demonstrated significantly worse survival rates in individuals with higher baseline OPG levels for all-cause and cardiovascular mortality (p |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |